Questions discussed in this category
The patient has ongoing inflammatory arthritis despite methotrexate, apremilast, and jak inhibitor trials.
What side effects do you highlight in conversation with them? How do you approach toxicity monitoring?
19672214111951221247196931690014664140878040
Papers discussed in this category
The Journal of rheumatology, 2012-01
JAAD Case Rep, 2019 Oct 10
Clinical rheumatology, 1988 Sep
Journal of the American Academy of Dermatology, 1987 Apr
Journal of the American Academy of Dermatology, 2020 May 19
Annals of the rheumatic diseases, 2024 Mar 18
Ann Rheum Dis, 2020 Dec 17
Expert review of anticancer therapy, 2009-01
Lancet Gastroenterol Hepatol, 2023 Feb 01